In a study from Slamon et al., trastuzumab added to a nonanthracycline regimen to treat HER2-positive breast cancer resulted in rates of disease-free and overall survival that were similar to those for an anthracycline-containing regimen, with lower rates of cardiac toxicity and secondary leukemia. The HER2 gene encodes a tyrosine kinase receptor that mediates critical… Read More…
In a new study from Conroy et al., a four-drug combination chemotherapy regimen was associated with objective responses in more than 30% of patients and increased survival by more than 4 months, as compared with standard gemcitabine. Pancreatic adenocarcinoma was the fourth leading cause of death from cancer in the United States in 2010, and… Read More…
The latest article in our Current Concepts review series, “Nanomedicine,” comes from Drs. Betty Kim, James Rutka, and Warren Chan of the University of Toronto. The field of nanomedicine aims to apply nanotechnology to the diagnosis and treatment of diseases at the molecular level. Clinical Pearls • What do nanomaterials consist of? Nanomaterials generally consist of… Read More…
Our latest article from the Current Concepts review series, “Triple-Negative Breast Cancer,” comes from Drs. William D. Foulkes, Ian E. Smith, M.D., and Jorge S. Reis-Filho, and focuses on its origin, molecular and clinical characteristics, and treatment. Triple-negative breast cancers are defined as tumors that lack expression of ER, progesterone receptor (PR), and HER2. Their… Read More…
